A Randomized, Open-label, Interventional, Real-world Study to Compare the Efficacy and Safety of QL0605 Administered at Different Timepoints After Chemotherapy.
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Aged≥18 years；
• The expected survival period is more than 3 months;
• ECOG≤ 2;
• Invasive breast cancer diagnosed by histopathology;
• Plan to receive TAC, TC or TCbH chemotherapy;
• Subjects with good hematology, liver, lung and kidney function ;
• Signed informed consent.
Locations
Other Locations
China
Shandong Cancer Hospital
RECRUITING
Jinan
Contact Information
Primary
Mengli Zhu, Master
mengli.zhu@qilu-pharma.com
13256715221
Backup
Wangwang Zhi, Master
wangwang.zhi@qilu-pharma.com
17761716313
Time Frame
Start Date: 2024-09-19
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 336
Treatments
Experimental: 24h group
Active_comparator: 48h group
Related Therapeutic Areas
Sponsors
Leads: Qilu Pharmaceutical Co., Ltd.